Sequoia Financial Advisors, Confluence Wealth Services, and Spire Wealth Management have increased their holdings in
Amgen Inc. Conversely,
Transcend Capital Advisors and Corundum Group Inc, among others, have reduced their stake.
Amgen's stock has seen fluctuations, with a notable drop by 5.8% when
Novo Nordisk outperformed in the weight loss drug trial. Despite these challenges, investors like
Jim Cramer argue that Amgen’s stock didn’t deserve this hard hit. Amidst the market cap decrease, global investments, such as those by
Sumitomo Mitsui Trust Group and Global Assets Advisory, suggest continued confidence in the company. Amgen's
weight loss drug, MariTide, has moved to phase 3 trial, causing a contrasting response from analysts with
Piper Sandler keeping an 'Overweight' rating while
Cantor Fitzgerald maintained a 'Neutral' rating. Amid safety concerns with MariTide trials,
Diversified Trust Co and Golden State Wealth Management continue to hold a substantial position in Amgen stock. Despite the drug trial debacle, Amgen is considered a good investment for long-term growth and value according to several analyses.
Amgen AMGN News Analytics from Mon, 24 Mar 2025 07:00:00 GMT to Sat, 28 Jun 2025 21:41:28 GMT -
Rating 6
- Innovation 3
- Information 8
- Rumor -2
